Hemostemix Closes First Tranche of Financing
May 16, 2019 08:30 ET
|
Hemostemix Inc.
NOT FOR DISTRIBTUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, May 16, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
Hemostemix Announces Convertible Debenture Financing
May 03, 2019 08:30 ET
|
Hemostemix Inc.
NOT FOR DISTRIBTUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, May 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
Hemostemix Announces Convertible Debenture Financing
April 15, 2019 08:30 ET
|
Hemostemix Inc.
NOT FOR DISTRIBTUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 15, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX...
Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
April 09, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, April 09, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has reached an enrollment...
Hemostemix Announces Appointment of Experienced Chief Medical Officer & President
April 01, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D,...
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
February 25, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA
February 04, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing...
Hemostemix Provides Highlights of 2018 Accomplishments
January 17, 2019 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on...
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
January 03, 2019 08:00 ET
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
November 09, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...